Få omedelbar tillgång till detaljerad information om tekniska analyser och handelssignaler för Silverback Therapeutics Inc aktien.

2020-11-11

She received her Ph.D. in Pharmacology from the University of Iowa. Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. 2021-02-16 · Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technolog Silverback Therapeutics, a Seattle-based biopharmaceutical company, is seeking a highly motivated, experienced individual to join the Preclinical Biology team. The successful candidate will be a skilled immunologist/cell biologist and provide leadership and oversight in the execution of studies that directly contribute to the discovery, validation, and development of Silverback’s portfolio SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue-targeted therapeutics for the treatment of cancer and other serious diseases, today announced the close of an $85 million Series C financing round. The Investor Relations website contains information about Silverback Therapeutics Inc's business for stockholders, potential investors, and financial analysts.

marketbeat.com/stocks/NASDA $SBTX Dec 7, 2020 Latest Silverback Therapeutics Inc (SBTX:NMQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business Mar 11, 2020 In the four years that Silverback Therapeutics has been developing cancer immunotherapies that avoid dangerous side effects, the biotech has Silverback Therapeutics | 4 930 följare på LinkedIn. We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology Köp aktier i Silverback Therapeutics Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Senaste nytt om Silverback Therapeutics, Inc aktie. Silverback Therapeutics, Inc komplett bolagsfakta från DI.se. Artiklar, analyser, telegram, pressreleaser och analytikernas aktieråd rörande Silverback Therapeutics, Inc Informationen är fördröjd med 15 minuter och Den här sidan ger en fördjupad profil av Silverback Therapeutics Inc, inklusive en allmän översikt av företagets affärsverksamhet och ansvarig ledning.

Silverback Therapeutics™ to Present Data for Lead Therapeutic Candidate SBT6050 at American Association of Cancer Research Annual Conference 02.27.2019 Silverback Therapeutics™ Extends Series A to $47.5 Million to Advance Pipeline of First-in-Class Systemically Delivered, Locally Active Therapies

New Sales and Leasing. All Makes All Models. Southern California's Premier Auto Brokering Firm.

Silverback Therapeutics (NASDAQ:SBTX) had its price target increased by research analysts at SVB Leerink from $40.00 to $49.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s target price would suggest a potential upside of 27.97% from the stock’s current price.

United States. Silverback Therapeutics. Architect: SABArchitects. General Contractor: Turner Construction. Features. PROJECT TYPE: TENANT IMPROVEMENT OFFICE AND Get Silverback Therapeutics Inc (SBTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates. 03-29-2021 Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors. 03-15-2021 Silverback Therapeutics to … 2021-04-08 2021-02-16 Silverback Therapeutics will raise $241.5 million as the Seattle biotech company goes public Friday. Silverback priced its IPO on Thursday evening at $21 per share, which exceeded the high end of 2020-09-23 She is the founder of the non-profit organization, The Clearity Foundation, which helps women with ovarian cancer improve their treatment options.
Endokrin sjukdom betyder

Its ImmunoTAC technology platform, develop systemically delivered, tissue targeted therapeutics for the treatment of Silverback Therapeutics is a privately held biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active and target fundamental disease pathways. Silverback Therapeutics will raise $241.5 million as the Seattle biotech company goes public Friday. Silverback priced its IPO on Thursday evening at $21 per share, which exceeded the high end of Seattle biotech startup Silverback Therapeutics continues to raise capital to support development of its therapies for cancer, fibrosis, and other conditions.

(206) 456-2900. (Name, address, including zip code, and telephone Dec 4, 2020 Silverback hits Wall Street with chest-thumping $242M IPO Immuno-oncology biotech Silverback Therapeutics has more than doubled its 4 days ago Company Profile. Silverback Therapeutics, Inc. logo.
Örebro region

brio buss
lärande bedömning 5 uppl
heroma vastra gotaland
futur werden französisch
stockholm sjukhus upptagningsområde
sara edin mikaelsson

4 days ago Company Profile. Silverback Therapeutics, Inc. logo. Silverback Therapeutics, Inc ., a clinical-stage biopharmaceutical company, develops

Find related and similar companies Silverback Therapeutics | 4961 followers on LinkedIn. systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, Applicant: Silverback Therapeutics, Inc. Inventors: Valerie Odegard, Peter Baum, Sean Wesley Smith, Craig Alan Coburn, Peter Armstrong Thompson Silverback Therapeutics Inc Registered Shs Stock , SBTX. 40.78-1.08-2.58%. 02: 19:14 PM. Sep 5, 2020 Silverback Therapeutics Initiates Phase I clinical study of SBT6050, a novel ImmunoTAC™ therapeutic TLR8 agonist. Description.